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It happens all the time: a pharmaceutical or biotechnology
company will spend ten years and hundreds of millions of
dollars on a drug candidate that looks spectacular in animal
models of a disease, only to see it fail during clinical trials,
either because of unexpected adverse reactions in a small
number of patients or a surprising lack of efficacy. For every
drug that is approved, on average more than 6,000 new
chemical substances are created. Only seven of these ever
end up being tested in humans, and only three make it to
Phase III clinical trials, the final step before a drug is
approved by the Food and Drug Administration in the US. It
takes over a decade and at least several hundred millions of
dollars - sometimes close to $1 billion - to get that far, and
even then, on average, only one of three candidates will
emerge from Phase III and become a marketed drug. 
This combination of colossal failure rate with astronomical
cost - unique to the pharmaceutical industry - is the main
reason new medicines are both expensive and hard to come
by. Despite advances in synthetic chemistry, high-throughput
screening, and structure-based drug discovery, the number of
new drugs approved has remained relatively constant, at
about 20-30 per year, for a quarter of a century. As human
lifespan increases, the demand for medicines to treat more
difficult diseases such as cancer, heart disease, autoimmune
disorders and neurodegeneration is likely to cause this
meager success rate to decline - which may already be hap-
pening, since many big drug firms currently have rather dry
pipelines. Such a trend could spell disaster for some of the
largest pharmaceutical companies, which have grown so big
through mergers that they need historically high returns on
investment just to survive. For many of them, only so-called
‘blockbuster’ drugs - those with projected annual sales in
excess of $1 billion a year - are now seen as worth developing. 
That would seem to leave much of the field clear to biotech-
nology, but the enormous cost of taking a drug all the way
through Phase III clinical trials means that most small
biotech pharmaceutical companies can’t manage it without
at some point partnering with one of the big firms. Industry
experts saw all this coming years ago. In the absence of some
transforming technology, it seemed to pose an unsolvable
conundrum: how to satisfy an increasing public demand that
the wave of exciting biological discoveries from academia
and biotech be translated into a vast array of new, cheaper,
better medicines, when the cost and time needed to do so
was steadily getting worse. 
No wonder the genomics revolution was viewed with such
hope. Even before the genome of the first free-living
organism was sequenced by Fraser, Venter and their
associates (Smith et al., Science 1995, 269:538-540), one of
the selling points of the human genome project was that it
would lead eventually to a new era, the era of pharmacoge-
nomics. The reason so many promising drugs failed so late
in the development process - in human trials - it was argued,
was that differences in individual human genome sequences
led to different profiles of gene expression, especially of
isozyme families such as the cytochrome P450 enzymes,
which carry out much of the metabolism of foreign substances,
like drugs, in the human body. Once these differences could be
determined for each patient, it would be possible to predict
who would be likely to suffer an adverse reaction to a particular
drug. Such people could simply be excluded from clinical trials
(and of course from later therapy), and consequently the
success rate for drug development would increase markedly. 
We’ve had the human genome sequence for a little while
now, and it looks as though we’re still some way off being
able to exclude from most clinical trials those people who
will probably suffer side effects. Toxicity is a complex, often
polygenic, process and we need to know more about it in
order to link it confidently with genomic information. But
two articles that have just appeared this month, in Science
(Paez  et al.,  Science 2004, DOI: 10.1126/science.1099314)
and the New England Journal of Medicine (Lynch  et al.,
N Engl J Med 2004, DOI: 10.1056/NEJMoa040938), make
it clear that the era of pharmacogenomics has neverthelessarrived. If they are any indication, and I think they are, this
era will begin not with ruling patients out on the basis of
likely toxicity, but rather with ruling them in on the basis of
likely efficacy. 
Both articles deal with the response of patients with non-
small-cell lung cancer (NSCLC), the leading cause of death
from cancer worldwide, to a new drug, gefitinib. (Most drugs
now have three names: a systematic chemical name, a
generic drug name, and a specific product name from the
company that first developed them. Thus the non-steroidal
anti-inflammatory drug called Advil in the US is Wyeth
Pharmaceutical’s name for its brand of ibuprofen, which in
turn is the generic name for the chemical substance
isobutylphenyl propionic acid. Iressa is the product name
given to gefitinib by the drug company AstraZeneca.) Gefitinib
targeted a molecule that was known to be overexpressed in
this cancer, and the drug looked very promising in animal
model studies, so it was both surprising and disappointing
when it was found in clinical trials that most NSCLC patients
had no response to gefitinib at all. Yet a small subset, about
10%, not only responded, but did so spectacularly - a
‘Lazarus response’, according to one physician, with com-
plete remission even of advanced disease. These patients
tended to have certain common characteristics: the majority
were nonsmokers and women. Moreover, Japanese patients
responded more frequently (about 25%) than did Caucasians.
All these data suggested a genetic basis for the efficacy of the
drug in such cases. 
The authors of both papers started with the same assumption,
that the first place to look for allelic variations among
patients was the gene for the target. Gefitinib is an inhibitor
of the epidermal growth factor receptor protein kinase
HER1, or EGFR. It binds to the ATP-binding site in the cat-
alytic domain of the kinase, blocking the enzyme’s ability to
phosphorylate protein substrates. Both teams of investiga-
tors sequenced the EGFR gene from tumor samples of both
responders and non-responders to the drug. They found that
nearly all the responders had heterozygous mutations in
their EGFR gene, while none of the non-responders did. The
mutations, which included both short deletions and single
amino-acid substitutions, tended to cluster around the ATP-
binding site. Moreover, when the receptor gene was
sequenced from a cohort of NSCLC patients who had not
been treated with gefitinib, similar mutations were found in
about 10% of them, exactly the percentage of responders in
the clinical trials. One of the studies even found that female
nonsmokers and Japanese patients showed a higher than
average incidence of the mutations, also correlating perfectly
with the clinical data. Taken together, these data strongly
suggested that the favorable response to the drug not only
correlated with, but was caused by, the mutated EGFR gene. 
Heterozygosity of the mutations implied they might produce
a gain of function. In vitro studies showed that the mutated
receptor was indeed more active than the wild-type, which
could account for its relatively high incidence in tumors -
presumably it confers some survival or growth advantage.
The assumption is that the altered ATP-binding site leads to
the increased activity, as well as to increased affinity for gefi-
tinib. Enzymological studies will be needed to establish
exactly how this occurs and whether it is the whole story.
No-one is concerned by the small number of responders who
were not found to have EGFR mutations in their tumors;
non-small-cell lung carcinomas, like other solid tumors, are
probably polyclonal. Presumably, had a different sample of
cells been sequenced, mutations would have been observed. 
It now seems clear that, for a subset of NSCLC patients, gefi-
tinib promises to be an effective treatment. Screening people
who present with this cancer for EGFR mutations in the
kinase domain is a trivial task, and ought to be the first step
in deciding what therapy to use. But if this is really the
dawning of the age of pharmacogenomics, the gefitinib story
can’t be an isolated case. 
Recent data suggests that it is not. A subset of breast cancer
patients overexpress a related receptor, HER2, on the
surface of their tumor cells. Many of these patients show a
good response to trastuzumab (Herceptin), Genentech’s
monoclonal antibody drug directed against this receptor.
Novartis’s drug imatinib (Gleevec), which also binds to the
ATP-binding site of its target, the Bcr-Abl protein kinase,
has shown considerable effectiveness against chronic myel-
ogenous leukemia, a disease in which this kinase is acti-
vated by a chromosomal translocation (producing the
so-called Philadelphia chromosome). The Bcr-Abl kinase
can transform hematopoietic cells and is essential for tumor
progression, explaining the efficacy of the drug for this
cancer. Interestingly, imatinib also appears to be effective
against a subset of gastrointestinal stromal cancers, and
responsive tumors have recently been found to contain
mutations in the c-Kit protein kinase (Heinrich et al., J Clin
Oncol 2003, 21:4342-4349). The hope is now that for many
cancers, at least a percentage will have proteins that are
essential for tumor progression, either through overexpres-
sion or mutation, and that these proteins will form the basis
for targeted therapy. 
When the first report came out that gefitinib was effective in
only a subset of NSCLC patients, science reporters and stock
analysts bemoaned the loss of income that AstraZeneca
would suffer. Given the pharmaceutical industry’s need for
blockbuster drugs, it might indeed seem that pharmaco-
genomics would be little, if any, help, if all it did was drastically
reduce the size of the potential market for a given drug. But
let’s do the sums. In the US alone, 140,000 people are diag-
nosed each year with NSCLC (the figure is about a million
worldwide). If about 10% of these turn out to have gefitinib-
responsive tumors, then the US market is on the order of
10,000. Gefitinib is expected to cost about $3,000 per
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cally, around $360 million per year. But 10,000 patients
per year is the rate of incidence, not prevalence: that many
new patients are expected to present with gefitinib-responsive
NSCLC each year. And each of them will probably need to take
the drug for the rest of their life. So the market for gefitinib
should rapidly grow to blockbuster size, even if only the US
market is considered. And for any such patients, for some time
to come, gefitinib will clearly be the front-line treatment, not
one of a host of alternatives as is the case with other forms of
cancer. That’s a recipe for the kind of profits even the biggest
drug company should be happy with. 
Pharmacogenomics might turn out to be an even bigger
boon to the biotechnology industry. Any biotech company
would be thrilled to have a revenue stream of a few hundred
million dollars a year: the problem is the cost of getting
there. But if clinical trials could be conducted with fewer
patients than is now the case, because the likely responders
could be identified in advance, and if that also translated
into fewer drug failures in late-stage clinical trials, then both
the cost and time to gain approval of a new drug could drop
substantially, perhaps to the point that even a small
company, or a joint venture of several of them, could go it
alone. Of course, for that to happen, the problem of adverse
reactions would also have to be solved, or at least greatly
mitigated. Pharmacogenomics hasn’t made an impact on
toxicity yet, but give it time. It’s only just arrived.
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